European Medicines Agency "Jansen vaccine, possibility of specific blood clot case"

The European Medicines Agency said it has discovered the possibility that the'Jansen' COVID-19 vaccine from Johnson & Johnson in the United States may have been associated with a specific case of blood clots accompanied by platelet reduction.

Earlier on the 13th, the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention also recommended discontinuation of use, saying it had identified six cases of'rare but severe' blood clots among Janssen vaccinations.

Since then, Janssen vaccination has been stopped or delayed in many parts of the world, including the United States.